Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2018 Apr 24;11(5):475–486. doi: 10.1080/17512433.2018.1464388

Table 2:

Completed clinical trials using CTLA-4 Inhibitors in Prostate cancer

Drug Phase Number of
patients		 Setting Results Reference
Ipilimumab I 14 mCRPC PSA50: 14% (2/14) 53
Ipilimumab + ADT II 108 Locally advanced PCa Undetectable PSA at 3 months:
ADT + Single dose of Ipilimumab: 55%
ADT alone: 38%		 54
Ipilimumab +− radiation therapy I/II 75 mCRPC after progression on an anti-androgen therapy PSA decline in evaluable patients:
3 mg/kg: 27% (4/15)
5 mg/kg: 17% (1/6)
10 mg/kg: 16% (8/50)		 55
Ipilimumab after radiation therapy III 799 mCRPC after progression on docetaxel OS 11.2 m for ipilimumab vs 10.0 m for placebo (HR 0.85, 0.72 – 1.00, p=0.053)
1 y OS 46.8% for ipilimumab vs 40.4% for placebo
2 y OS 26.2% for ipilimumab vs 15.0% for placebo
PFS 4.0 m for ipilimumab vs 3.1 m for placebo (HR 0.70, 0.61 – 0.82, p< 0.0001)
PSA50 response 13.1% for ipilimumab vs 5.2% for placebo
 56
Ipilimumab III 400 Asymptomatic or minimally symptomatic mCRPC chemotherapy naïve OS 28.7 m for ipilimumab vs 29.7 for placebo (HR 1.1, 0.88 – 1.39, p=0.3667).
PFS 5.6 m for ipilimumab vs 3.8 m for placebo (HR 0.67, 0.55 – 0.81)
PSA50 response 23% vs 8%		 57